Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on AKTX. Alliance Global Partners started coverage on Akari Therapeutics in a research note on Tuesday, November 1st. They set a “buy” rating and a $4.00 target price for the company. HC Wainwright assumed coverage on Akari Therapeutics in a report on Monday, December 5th. They set a “buy” rating and a $1.50 target price for the company.

Akari Therapeutics Stock Down 1.8 %

Shares of AKTX stock opened at $0.49 on Tuesday. The stock has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.74. Akari Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.61. The stock has a market capitalization of $36.54 million, a P/E ratio of -1.40 and a beta of 1.32.

Institutional Investors Weigh In On Akari Therapeutics

Several hedge funds have recently modified their holdings of the stock. Armistice Capital LLC purchased a new stake in shares of Akari Therapeutics during the third quarter valued at $2,703,000. Omnia Family Wealth LLC lifted its stake in Akari Therapeutics by 3.2% in the 3rd quarter. Omnia Family Wealth LLC now owns 782,372 shares of the biopharmaceutical company’s stock worth $493,000 after acquiring an additional 24,228 shares in the last quarter. Finally, LPL Financial LLC purchased a new stake in Akari Therapeutics in the 2nd quarter worth about $83,000. 13.59% of the stock is owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

(Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Featured Stories

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.